A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.

A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats. The study is in the October issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

About half of California adults diagnosed with high blood pressure, or hypertension, do not take medication to lower it, researchers reported today at the American Heart Association’s 61st Annual Fall Conference of the Council for High Blood Pressure Research.

A new study by researchers at the University of Southern California suggests that some TV may be good for you.

Patients with high blood pressure respond very differently to antihypertensive medication, making treatment selection tricky for physicians. But new research published in the online open access journal, BMC Medical Genetics, pinpoints a number of gene-drug interactions that could allow medication to be tailored to individual patients based on their genetics.

Beta blockers should be the first line of prevention against variceal bleeding in patients with cirrhosis and portal hypertension. While banding is similarly effective in reducing the incidence of such bleeding, it can have fatal complications and is more expensive.

In a study of children and adolescents with hypertension, only about one in four had been previously diagnosed with the condition, according to a study in the August 22/29 issue of JAMA.

Exercise cannot reduce a sodium-retaining hormone in African Americans known to potentially cause hypertension, found Michael D. Brown, Ph.D., the senior author of a study in the September issue of Experimental Physiology. Brown is an associate professor of kinesiology at Temple University’s College of Health Professions.

Many people with long-standing high blood pressure develop heart failure. But some don't. Daniel P. Kelly, M.D., and colleagues at Washington University School of Medicine in St. Louis and other institutions are trying to figure out what could explain that difference.

Menopausal women are at relatively high risk for memory loss, high blood pressure (hypertension) and diabetes. A decade ago, the standard treatment for these problems was long-term hormone replacement therapy (HRT).

Many common diseases exhibit gender bias and gender differences have been observed in the development of high blood pressure (hypertension) and heart (cardiovascular) disease. Previous studies have reported that gender may affect vascular physiology and the body’s response to some types of blood pressure medications.

The distrust of healthcare providers shown by people with high blood pressure impedes effective treatment, as emphasized in a new study published in Journal of the American Academy of Nurse Practitioners.